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Atopic dermatitis increases the effect of exposure to
peanut antigen in dust on peanut sensitization and likely
peanut allergy
Helen A. Brough, MSc, FRCPCH,a Andrew H. Liu, MD,b Scott Sicherer, MD,c Kerry Makinson, MSc,a Abdel Douiri, PhD,e
Sara J. Brown, MD,d Alick C. Stephens, PhD,a W. H. Irwin McLean, PhD, DSc, FRSE, FMedSci,d Victor Turcanu, PhD,a
Robert A. Wood, MD,f Stacie M. Jones, MD,g Wesley Burks, MD,h Peter Dawson, PhD,i Donald Stablein, PhD,i
Hugh Sampson, MD,c* and Gideon Lack, MDa* London and Dundee, United Kingdom, Denver, Colo, New York, NY,
Baltimore and Rockville, Md, Little Rock, Ark, and Chapel Hill, NC
Background: History and severity of atopic dermatitis (AD) are
risk factors for peanut allergy. Recent evidence suggests that
children can become sensitized to food allergens through an
impaired skin barrier. Household peanut consumption, which
correlates strongly with peanut protein levels in household dust,
is a risk factor for peanut allergy.
Objective: We sought to assess whether environmental peanut
exposure (EPE) is a risk for peanut sensitization and allergy and
whether markers of an impaired skin barrier modify this risk.
Methods: Peanut protein in household dust (in micrograms per
gram) was assessed in highly atopic children (age, 3-15 months)
recruited to the Consortium of Food Allergy Research
Observational Study. History and severity of AD, peanut
sensitization, and likely allergy (peanut-specific IgE, >_5 kUA/
mL) were assessed at recruitment into the Consortium of Food
Allergy Research study.
Results: There was an exposure-response relationship between
peanut protein levels in household dust and peanut skin prick
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test (SPT) sensitization and likely allergy. In the final
multivariate model an increase in 4 log2 EPE units increased the
odds of peanut SPT sensitization (1.71-fold; 95% CI, 1.13- to
2.59-fold; P 5 .01) and likely peanut allergy (PA; 2.10-fold;
95% CI, 1.20- to 3.67-fold; P < .01). The effect of EPE on peanut
SPT sensitization was augmented in children with a history of
AD (OR, 1.97; 95% CI, 1.26-3.09; P < .01) and augmented even
further in children with a history of severe AD (OR, 2.41; 95%
CI, 1.30-4.47; P < .01); the effect of EPE on PA was also
augmented in children with a history of AD (OR, 2.34; 95%
CI, 1.31-4.18; P < .01).
Conclusion: Exposure to peanut antigen in dust through an
impaired skin barrier in atopically inflamed skin is a plausible
route for peanut SPT sensitization and PA. (J Allergy Clin
Immunol 2015;135:164-70.)
Key words: Atopic dermatitis, peanut sensitization, peanut allergy,
environmental peanut exposure, dust
Skin barrier dysfunction plays an important role in the
development of atopic dermatitis (AD),1,2 and AD is often cited
as the first step in the allergic march.3,4 There is a clear association
between early-onset AD and food allergy5,6 and a growing body
of evidence that epicutaneous exposure to peanut through an
impaired skin barrier increases the risk of peanut sensitization
and clinically confirmed peanut allergy.7-9 Among children with
peanut allergy with AD in the Avon Longitudinal Study of Parents
and Children, 90% had been exposed to creams containing
Arachis (peanut) oil in the first 6 months of life.6 In BALB/c
mice epicutaneous peanut exposure has been shown to induce a
potent allergic TH2-type response and anaphylaxis after a single
oral antigen challenge7-9; however, in these studies this was
only achieved if skin stripping, leading to skin barrier impairment
and inflammation, was performed before antigen application. In
flaky tail mice that carry a mutation within the murine flg gene,
topical application of ovalbumin leads to a cellular infiltrate and
antigen-specific antibody response, even without skin stripping.10
We have shown that early exposure to peanut antigen in
household dust is a risk factor for the development of peanut
sensitization and clinically confirmed peanut allergy in
children who carry a filaggrin (FLG) null mutation in the
Manchester Asthma and Allergy Study cohort.11 In another
study environmental exposure to peanut measured indirectly
based on household peanut consumption was associated with
peanut allergy, particularly when compared with atopic
children.12 Peanut protein in household dust was not
objectively quantified in this study; however, other studies
have measured peanut allergens in dust,13,14 and we have
shown that peanut allergen levels in dust from the infant’s
bed and play area correlate with household peanut consump-
tion and stimulate an allergic response in effector cells of
patients with peanut allergy.15
We hypothesized that an impaired skin barrier in children
with AD or FLG null mutations would modify the effect of
environmental peanut exposure (EPE), as defined by peanut
protein in household dust (in micrograms per gram), on
peanut sensitization and allergy. If proved, this hypothesis
would support the notion that a primary mode leading to
the development of peanut sensitization and allergy occurs
through presentation of environmental peanut antigen through
an impaired skin barrier to underlying antigen-presenting cells.
The purpose of this study was to assess whether early EPE
increases the risk of peanut sensitization and allergy in young
atopic children.
METHODS
Participants were from the National Institutes of Health–sponsored
Consortium of FoodAllergy Research (CoFAR). The design andmethodology
are described elsewhere.16 In brief, 512 children less than 15 months of age
were recruited with a convincing clinical history of cow’s milk allergy, egg
allergy, or both and a positive skin prick test (SPT) response to cow’s milk,
egg, or both, respectively, or with moderate-to-severe AD with a positive
SPT response to cow’s milk, egg, or both but without known peanut allergy.
Study procedures were reviewed and approved by a National Institute of
Allergy and Infectious Diseases Data Safety Monitoring Board and by local
institutional review boards, and written signed informed consent was
obtained. The analyses included 359 (70.1%) of 512 participants who
provided enough dust to analyze approximately 10 mg for peanut protein.
SPTs were performed with the GreerPick (Greer Laboratories, Lenoir, NC)
on the infant’s back. Results were obtained after 15 minutes, and the average
mean wheal diameter (after subtraction of the saline negative control) was
recorded. Children with peanut SPT responses of 3 mm or greater were
described as peanut SPT sensitized, and childrenwith peanut SPT responses of
less than 3 mm were described as not sensitized. Children with serum specific
IgE (sIgE) to peanut (ImmunoCAP system; Thermo Fisher Scientific,
Uppsala, Sweden) of 0.35 kUA/mL or greater were described as peanut sIgE
sensitized. Children with serum sIgE levels to peanut of 5 kUA/mL or greater
were described as having a serologic diagnosis of likely peanut allergy (PA);
this was postulated as in previous studies, 70% to 90% of 5- to 7-year-old
children had positive diagnostic peanut challenge results with this level of
peanut sIgE.17-19 Children were defined as not peanut allergic if they had a
history of tolerating eating peanut (regardless of sensitization status) or if
they were not sensitized to peanut, even if there was no history of peanut
ingestion. Peanut-sensitized children (peanut SPT response >_3 mm or peanut
sIgE level of between 0.35 and 5 kUA/mL) without a history of peanut
ingestion were excluded from the PA analysis because they did not undergo
a peanut challenge at baseline and thus could not be defined as having peanut
allergy or peanut tolerance. Of 359 subjects with available living room dust,
150 (41.8%) children had no history of ingestion of peanut and peanut SPT
responses of 3 mm or greater or sIgE levels of 0.35 kUA/mL or greater and
thus were excluded from the PA analysis. Of the remaining children, 89
(42.6%) of 209 were considered to have a serologic diagnosis of PA because
of a peanut sIgE level of 5 kUA/mL or greater. There were 120 children
considered not to have peanut allergy who either reported peanut consumption
without a reaction (n 5 20/209 [9.6%]) or who were not sensitized to peanut
(n 5 100/209 [47.8%]).
FLG genotyping was performed with genomic DNA extracted from blood.
The FLG null mutations R501X, 2282del4, S3247X, and R2447X were
assessed with a TaqMan-based allelic discrimination assay (Applied
Abbreviations used
AD: Atopic dermatitis
CoFAR: Consortium of Food Allergy Research
EPE: Environmental peanut exposure
FLG: Filaggrin
IQR: Interquartile range
LLQ: Lower limit of quantitation
LR: Logistic regression
OR: Odds ratio
PA: Peanut allergy
sIgE: Specific IgE
SPT: Skin prick test
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Biosystems, Life Technologies, Cheshire, United Kingdom) by using
previously described probes and primers.20,21 History of AD and maximum
severity of ADwere graded by (1) extent of disease (by ‘‘rule of 9’’), (2) course
of disease (by history), and (3) intensity of disease (disturbance of night’s
sleep by itching), each on a 3-point scale, as previously described.22 The
rule of 9 is used to calculate the area of the body’s skin affected for SCORAD
score assessment, where the head and neck amount to 9%, the upper
limbs amount to 9% each, the lower limbs amount to 18% each, the anterior
trunk amounts to 18%, the back amounts to 18%, and the genitals amount
to 1%.23
EPE was quantified from dust collected at baseline from the family’s living
room floor. Families were asked to avoid vacuuming their living room floors
for 3 days before obtaining dust. Participants were provided with a
DUSTREAM adaptor and collector (Indoor Biotechnologies, Warminster,
United Kingdom), a nylon collection filter, a disposable template, and
instructions for vacuuming. The living room floor was vacuumed for 2
minutes within a 1-m2 surface area. Dust samples were sieved, and fine dust
was extracted in a proportional volume of extraction solution.24 Peanut protein
in dust was determined by using the Veratox polyclonal ELISA against whole
peanut protein (Neogen, Lansing, Mich), which has been validated for
sensitivity, specificity, and reliability in measuring peanut protein in
food25,26 and dust.24 The lower limit of quantification (LLQ) of the assay
was defined as 100 ng/mL whole peanut (25 ng/mL peanut protein), and
samples of less than this value were defined as LLQ/2 (12.5 ng/mL peanut
protein, which equated to between 1.05 and 1.23 mg/g depending on the
weight of dust obtained).27 There were 16 (4.5%) of 359 living room dust
samples with peanut protein levels of less than the LLQ. Results were
converted from nanograms per milliliter into micrograms of peanut protein
per gram of dust. Participant information was kept blind from the researcher
performing the ELISA dust analyses. Dust samples were also obtained from
the infant’s bed dust; details are described in the Methods section in this
article’s Online Repository at www.jacionline.org.
Statistical analysis
Data were entered into SPSS (SPSS 19.0; SPSS, Chicago, Ill) and STATA
(STATA/IC 12.1; StataCorp, College Station, Tex) spreadsheets for analysis.
Associations between demographic, clinical, and household factors and
peanut SPT sensitization and PAwere assessed by using a logistic regression
(LR) model for children with available dust for analysis. Peanut protein
levels in dust (micrograms per gram) underwent log2 transformation to
normalize data. EPE spanned approximately 12 log2 scales (1.05-3761.68
mg/g), and therefore we showed the effect of 4 log2 unit increases in EPE
on peanut SPT sensitization and PA. In a stepwise process all factors with
a trend toward an association with peanut SPT sensitization or PA on
univariate analysis (P < .15) were included in the multivariate model, and
then only those covariates with a P value of less than .05 were included
in the final multivariate model. The same covariates were included in the
multivariate analysis for all children, children with a history of AD, and
children with a history of severe AD. We assessed EPE as a continuous
variable and as quartiles by dividing the span of continuous EPE into 4
equal groups. Visual graphs were inspected, and the linearity of the logit
(p/[12p]) and log2 continuous peanut protein level was reasonable for
both peanut SPT sensitization and PA on univariate analysis. Overlapping
95% CIs of odds ratios (ORs) among EPE quartiles supported the linearity
of the exposure-response relationship between log2 EPE and the logit of
Prob (peanut SPT sensitization 5 positive) and Prob (PA 5 positive).
Therefore we used continuous EPE as the optimum representation of the
primary exposure variable throughout the article.
The effect of EPE on peanut sensitization or PAwas assessed in a univariate
and multivariate LR model in all children and subgroups of children without a
history of AD, with a history of AD, or with a history of severe AD. We
subsequently included an interaction termwith EPE and a history of AD (vs no
AD) or history of severe AD (vs no AD). To establish the relationship between
EPE during the child’s early life and maternal peanut consumption in
pregnancy, peanut protein levels in living room dust (in micrograms per
gram) were compared in homes in which mothers either avoided or consumed
peanut during pregnancy by using the Mann-Whitney U test. Statistical
significance was assessed at a P value of less than .05.
RESULTS
EPE is associated with peanut SPT sensitization
and PA
ORs (95% CIs) of factors possibly associated with peanut SPT
sensitization or PA (peanut sIgE, >_5 kUA/mL) are displayed in
Tables I (univariate LR analysis), II, and III (multivariate LR
analyses). There was a significant association between a 4-unit
log2 increase in EPE and peanut SPT sensitization both on univar-
iate analysis (n5 359; OR, 1.52; 95% CI, 1.08-2.14; P5 .01) and
multivariate LR analysis (n 5 292; OR, 1.71; 95% CI, 1.13-2.59;
P5 .01), adjusting for parental report of hay fever ever in the child,
egg SPT wheal diameter (in millimeters), and maternal peanut
consumption during pregnancy and breast-feeding (which were
also associated with peanut SPT sensitization at P < .05). There
was a trend toward an association between EPE and PA on
univariate analysis (n 5 209; OR, 1.46; 95% CI, 0.92-2.29;
P5 .11) and a significant association on multivariate LR analysis
(n 5 209; OR, 2.10; 95% CI, 1.20-3.67; P < .01), adjusting for
ethnicity, egg SPT wheal diameter, and cow’s milk SPT wheal
diameter (which were also associated with PA at P < .05). The
relationship between peanut protein in the infants’ bed and peanut
SPT sensitization and PA is described in this article’s Online
Repository at www.jacionline.org.
History of AD modifies the effect of EPE on peanut
SPT sensitization and PA
On stratified univariate analysis, the effect of increasing EPE on
peanut SPT sensitization and PAwas augmented in childrenwith a
history of AD and severe AD (Fig 1, A: peanut SPT sensitization;
Fig 1, B: PA). On univariate analysis, there was a significant inter-
action between EPE and AD on the risk of peanut SPT sensitiza-
tion (OR, 1.41; 95% CI, 1.01-1.97; P < .05) per log2 unit EPE
increase; this further increased when comparing the interaction
between EPE and a history of severe AD (OR, 1.46; 95% CI,
1.04-2.07; P < .05). The interaction between EPE and a history
of AD did not reach statistical significance for PA. There was no
association between EPE and peanut SPT sensitization (OR,
0.81; 95% CI, 0.59-1.12) or PA (OR, 0.95; 95% CI, 0.60-1.49)
in children without a history of AD.
On multivariate LR analysis, the exposure-response relation-
ship of EPE was augmented in children with a history of AD for
peanut SPT sensitization (OR, 1.97; 95% CI, 1.26-3.09; P < .01)
and PA (OR, 2.34; 95% CI, 1.31-4.18; P < .01; Table IV). For
peanut SPT sensitization, the effect of EPE was further
augmented in children with a history of severe AD (OR, 2.41;
95% CI, 1.30-4.47; P < .01); however, a similar increase
was not observed for PA. In the multivariate predictive
probability figures, the association between EPE and peanut
SPT sensitization and PA remained; however, there was no
longer a clear differentiation of the effect of EPE among all
children, children with a history of AD, and children with a
history of severe AD (see Fig E1, A, in this article’s Online
Repository at www.jacionline.org: peanut SPT sensitization;
see Fig E1, B: PA).
The interaction between EPE and a history of AD for the risk of
peanut SPT sensitization remained significant in the multivariate
J ALLERGY CLIN IMMUNOL
JANUARY 2015
166 BROUGH ET AL
model; the OR was 1.48 (95% CI, 1.01-2.17; P < .05) per log2 unit
EPE increase in children with a history of AD versus those with no
AD, and the ORwas 1.56 (95% CI, 1.04-2.34, P5 .03) in children
with a history of severe AD versus those with no AD. In the final
multivariatemodel therewas a trend toward an interaction between
EPE and a history of AD for PAwith an OR of 1.68 (95%CI, 0.91-
3.12; P5 0.10) and an OR of 1.68 (95%CI, 0.85-3.31; P5 .14) in
children with a history of severe AD versus those with no AD.
FLG genotype on peanut sensitization and PA
The prevalence of FLG null mutations in white children with
AD (with dust available) was 14.9% (41/275); of these children,
37 had FLG heterozygote mutations, 3 had a combined
heterozygote mutations, and 1 had a 2282del4 homozygous
mutation. There was no significant association between FLG
heterozygous or compound heterozygous/homozygous mutations
and peanut SPT sensitization/PA; there was also no interaction
between FLG genotype and EPE.
Comparisons of the included group (n 5 359) with
available living room dust and the excluded group
(n 5 153)
Therewas no difference in the rate of peanut sensitization or PA
between subjects with (n 5 359) versus those without (n 5 153)
available dust; however, there were small but significant
differences in the rate of severe AD, ethnicity, number of older
siblings, maternal history of AD, maternal peanut consumption
during breast-feeding, and peanut present in the home while
breast-feeding (see Table E1 in this article’s Online Repository at
www.jacionline.org).
DISCUSSION
In this high-risk atopic cohort we found that EPE, as assessed
by log2 transformed peanut protein (in micrograms) per gram of
living room dust was a risk factor for peanut SPT sensitization
and PA (peanut sIgE, >_5 kUA/mL). After adjustment, an increase
in 4 log2 EPE units increased the odds of peanut SPT sensitization
1.71-fold (95% CI, 1.13- to 2.59-fold) and the odds of PA
2.10-fold (95% CI, 1.20- to 3.67-fold). The effect of EPE on
TABLE I. Unadjusted ORs and 95% CIs measuring associations between peanut SPT sensitization and likely PA and log2 EPE units
and subject demographic, clinical, and household factors*
Peanut SPT sensitization (n 5 359 [54.6% positive]) Likely PA (n 5 209 [42.6% positive])
OR 95% CI P value OR 95% CI P value
4 log2 EPE (mg/g) 1.52 1.08-2.14 .01 1.46 0.92-2.29 .11
History of infantile AD 1.83 0.82-4.06 .14 1.87 0.63-5.51 .26
Maximum AD severity before entry
No AD (0) Reference category Reference category
Mild (3-4) 2.46 0.88-6.89 .09 1.31 0.31-5.53 .71
Moderate (5-6) 1.77 0.75-4.19 .19 1.91 0.60-6.08 .28
Severe (7-9) 1.77 0.78-4.01 .17 1.94 0.64-5.88 .24
Nonwhite ethnicity 1.73 0.44-2.21 .23 1.93 1.04-3.60 .04
FLG null mutation (excluding nonwhite subjects) 0.72 0.37-1.39 .32 1.29 0.54-3.08 .56
Parental report of hay fever ever in the child 3.07 1.28-7.32 .01 1.52 0.57-4.20 .39
Male sex 0.82 0.53-1.28 .38 1.49 0.81-2.73 .20
Maternal history of atopy or asthma 1.29 0.83-2.02 .26 1.26 0.69-2.28 .45
Paternal history of atopy or asthma 1.00 0.65-1.54 1.0 1.00 0.56-1.78 1.0
Maternal history of AD 0.94 0.56-1.59 .82 1.13 0.56-2.28 .73
Paternal history of AD 0.74 0.42-1.30 .29 0.57 0.25-1.28 .17
Peanut consumption in pregnancy 1.67 0.94-2.26 .08 1.49 0.65-3.40 .34
Peanut consumption while breast-feeding 0.69 0.43-1.10 .12 0.51 0.27-0.94 .03
Peanut butter in house while breast-feeding 1.04 0.64-1.69 .88 0.94 0.49-1.78 .84
Older siblings 1.34 0.87-2.04 .18 1.11 0.63-1.95 .73
Egg SPT wheal diameter (mm) 1.15 1.10-1.21 <.01 1.26 1.17-1.35 <.01
Cow’s milk SPT wheal diameter (mm) 1.07 1.03-1.11 <.01 1.21 1.09-1.35 <.01
Duration of breast-feeding (mo) 1.05 1.00-1.10 .08 1.12 1.04-1.20 <.01
Maternal age at baseline (y) 1.02 0.99-1.07 .12 1.02 0.97-1.08 .40
Child’s age at baseline assessment (mo) 1.11 1.04-1.19 <.01 1.04 0.96-1.14 .34
Statistically significant values (P < .05) are shown in boldface.
*Descriptive statistics of subject factors and EPE are shown in Table E1.
ORs for EPE reflect a 4-unit increase in log2 EPE. ORs for other continuous factors reflect a 1-unit increase in the factor unit. These include egg SPTwheal diameter, cow’s milk,
duration of breast-feeding, maternal age at baseline, and child’s age at baseline. ORs for AD severity compare each severity level with the level ‘‘no AD.’’ All other factors are
dichotomous. ORs compare yes with no, ever with never, or male with female.
TABLE II. Adjusted peanut sensitization (OR [95% CI])
measuring associations between EPE and subject factors
(n 5 292)*
OR 95% CI P value
4 log2 EPE (mg/g) 1.71 1.13-2.59 .01
Egg SPT wheal diameter (mm) 1.17 1.11-1.24 <.001
Maternal peanut consumption in pregnancy 2.77 1.24-6.20 .01
Maternal peanut consumption while
breast-feeding
0.46 0.25-0.85 .01
Parental report of hay fever ever in the child 3.88 1.35-11.15 .01
Subject factors and EPE values are significant at the 5% level (in boldface). The OR of
EPE represents an increase of 4 log2 EPE units (in micrograms per gram).
*Sample size was reduced from 359 to 292 because of missing data for some factors in
the multivariate analysis.
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peanut SPT sensitization and PA increased in an exposure-
dependent manner in children with a history of AD, with an
increase in odds of 1.97 and 2.34, respectively. The effect of
EPE on peanut SPT sensitization was further augmented in
children with a history of severe AD; however, this was not the
case for PA, which might be due to the smaller sample size of
this group. There was a significant interaction between EPE and
the history and severity of AD for peanut SPT sensitization,
with a trend toward an AD-EPE interaction for PA. Given that
peanut sensitization and allergy are more common in children
with a history of AD,5,6 these data suggest that environmental
exposure to peanut through an impaired skin barrier is a plausible
route for peanut sensitization and allergy. The relationship
between peanut protein in the infants’ bed and peanut SPT
sensitization and PA is discussed in this article’s Online
Repository at www.jacionline.org.
The egg-induced SPTwheal diameter was also associated with
peanut SPT sensitization and PA. Egg allergy is known to be a
strong predictor of peanut sensitization and allergy.28 The cow’s
milk–induced SPT wheal diameter was also associated with
peanut SPT sensitization and PA; however, it lost significance
on multivariate analysis for peanut SPT sensitization, and this
might just be another marker of atopy. Environmental exposure
to peanut was not a risk factor for egg SPT sensitization or milk
SPT sensitization, confirming the specificity of environmental
peanut levels on peanut sensitization rather than food sensitiza-
tion in general. Nonwhite ethnicity (black, Asian, and other
nonwhite races combined) was associated with a peanut sIgE
level of 5 kUA/L or greater but not peanut SPT sensitization.
This supports the findings of the Learning Early About Peanut
(LEAP) study, in which black race was associated with a higher
peanut sIgE level but a lower peanut SPT response in the baseline
screening data from the LEAP study.28
FLG null mutations were not associated with peanut
sensitization or PA. This differs from previous published findings;
children with 1 of moreFLG null mutations were found to have an
increased risk of challenge-proven peanut allergy in white indi-
viduals from 4 different populations (United Kingdom, Irish,
Dutch, and Canadian).29 The lack of association with FLG geno-
type might be because in CoFAR children already had a 92.5%
history of AD and a 54.3% history of severe AD; thus the skin bar-
rier was already impaired, irrespective of whether children had
FLG null mutations. In addition, the rate of FLG null mutations
was surprisingly low in this cohort (14.9%) given the high rate
and severity of AD; previous studies have shown that FLG null
mutations are present in up to 56% of children with moderate-
to-severe AD.21,30 This might reflect a more varied genetic
background in the white American population.31 Another
potential explanation for the low FLGmutation rate in this cohort
is that 104 children with known PA or peanut sIgE >5 kUA/L were
excluded from the CoFAR study before enrollment. If these
children had been included, we would have expected a higher
rate of FLG null mutations, given the known association between
peanut allergy and FLG null mutations.29 A further explanation
could be that in children with cow’s milk and egg allergy (one
of the inclusion criteria for the CoFAR observational cohort),
exposure to cow’s milk or egg allergens through breast milk or
small quantities in food might have led to more severe AD.
Previously, the CoFAR study showed that frequent (>_2 times
weekly) maternal peanut consumption during the last trimester of
pregnancy was a risk factor for a peanut sIgE level of 5 kUA/L or
greater (OR, 2.9; 95% CI, 1.7-4.9).32 In the subgroup of children
with available dust samples (n 5 359), maternal peanut
consumption during pregnancy (any trimester) was associated
with peanut SPT sensitization (adjusted OR, 2.66; 95% CI,
1.18-5.99) but not with a peanut sIgE level of 5 kUA/L or greater
(P >.3); frequent maternal peanut consumption (>_2 times weekly)
in the last trimester showed only a trend toward an association
with a peanut sIgE level of 5 kUA/L or greater (P 5 .15). The
lack of significance for this might be due to the smaller sample
size of children with available dust; however, maternal peanut
consumption during pregnancy might simply be an indirect
marker of EPE. Levels of peanut protein in living room dust
were significantly greater in households in which mothers
TABLE III. Adjusted likely PA (OR [95% CI]) measuring
associations between EPE and subject factors (n 5 209)*
OR 95% CI P value
4 log2 EPE (mg/g) 2.10 1.20-3.67 <.01
Egg SPT wheal diameter (mm) 1.25 1.15-1.36 <.001
Nonwhite ethnicity 2.59 1.21-5.58 .02
Cow’s milk SPT wheal diameter (mm) 1.14 1.06-1.22 <.001
Subject factors and EPE values are significant at the 5% level (in boldface). The OR of
EPE represents an increase of 4 log2 EPE units (in micrograms per gram).
*The sample size was reduced from 359 to 209 because of missing data for some
factors in the multivariate analysis.
FIG 1. A, Univariate stratified predictive probability for the effect of
EPE (displayed in log2 [microgram per gram] units and untransformed
[microgram per gram] units) for peanut SPT sensitization in all children,
children with a history of AD, and children with a history of severe AD.
B,Univariate stratified predictive probability for the effect of EPE (displayed
in log2 [microgram per gram] units and untransformed [microgram per
gram] units) for likely PA in all children, children with a history of AD,
and children with a history of severe AD.
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consumed peanuts during pregnancy (median, 45.2 mg/g;
interquartile range [IQR], 17.5-161.8 mg/g) versus households
in which mothers avoided peanuts during pregnancy (median,
16.6 mg/g; IQR, 4.3-72.2 mg/g; P 5 .001). A prospective study
would be required in which maternal peanut consumption during
pregnancy was controlled and household peanut consumption
was subsequently compared with peanut protein in household
dust throughout early childhood to tease out the effect of maternal
peanut consumption during pregnancy and EPE during infancy.
The limitations of this study included missing living room dust
samples in 153 (30%) of 512 participants, which might have
introduced an element of bias. A serologic diagnosis of PA (sIgE,
>_5 kUA/L) rather than one based on oral food challenges was
used, which meant that 150 children were excluded because of
uncertainty about their peanut allergy outcome; this could also
have introduced bias. Children with known peanut allergy were
excluded at baseline; these children might have had even higher
peanut protein levels in living room dust and thus even steeper
predictive probability curves for peanut sensitization and PA.
Subjects recruited who did not have moderate-to-severe AD had
either cow’s milk or egg allergy; this might have led to an unusual
association between EPE and peanut SPT sensitization or PA in
children with no history of AD. The dust sample obtained was a
single baseline collection from one area of the home and thus
might be prone to variation; however, previous studies have
shown high within-home correlation of peanut protein levels in
dust, and peanut protein levels from a single dust collection
have been shown to correlate strongly with household peanut
consumption over the previous 6-month period.15 Peanut protein
levels in dust from the living-room floor were positively
correlated with those found in the infants’ bed (see Fig E2 in
this article’s Online Repository at www.jacionline.org). There
was no detailed assessment of infant peanut consumption, which
could potentially protect a child from high EPE, as per the
findings of Fox et al,12 who showed that children who consumed
peanut in the first year of life were not affected by high household
peanut consumption. Animal data suggest that oral allergen
exposure prevents induction of allergy,33 whereas epicutaneous
exposure prevents induction of oral tolerance.8 The role of early
high-dose peanut consumption on the prevention of peanut
allergy is currently being investigated28 but has already been
suggested in cross-sectional observational studies.34
In summary, these findings demonstrate a positive association
between exposure to peanut protein in dust and peanut SPT
sensitization and PA in atopic children. The effect of EPE on
peanut sensitization and PA was augmented in children with a
history of AD and severe AD for peanut sensitization
after adjusting for other covariates. This provides biological
plausibility that EPE might be sensitizing children through an
impaired skin barrier, thus supporting the hypothesis of
epicutaneous sensitization. We demonstrated the specificity of
EPE on peanut SPT sensitization and PA by showing that EPE
does not increase the risk of egg or cow’s milk SPT sensitization;
however, it would be interesting to assess the effect of other food
allergens in dust and respective sensitization and allergy to these
foods. Routes of exposure to food antigens appear to be crucial in
determining whether food allergy or tolerance develops as
per the dual-allergen exposure hypothesis.35,36 Although early
consumption of food will inevitably lead to higher environmental
exposure to foods, there are currently studies in place assessing
the role of oral tolerance induction in young children (www.
leapstudy.co.uk and www.eatstudy.co.uk); should these strategies
fail to prevent the development of food sensitization and allergy,
the alternative strategy of reducing environmental exposure to
food allergens could be considered.
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Key messages
d Increased environmental exposure to peanut protein is
associated with an increased risk of sensitization and
likely allergy to peanut in atopic children.
d The effect of peanut dust exposure on peanut sensitization
is augmented in children with a history of and increasing
severity of AD.
d The data are consistent with the hypothesis that allergic
sensitization to peanut occurs through an impaired and
inflamed skin barrier.
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METHODS
EPE was also quantified from dust collected at baseline from the infant’s
bed. Families were asked to avoid changing their infant’s bed sheet for 3 days
before obtaining dust. Peanut protein levels in bed dust versus living room dust
(in micrograms per gram) were compared by using the Mann-Whitney U test
and the Spearman rank correlation coefficient (rs); additionally, Pearson
correlation was used to compare log2 transformed peanut protein levels
(inmicrograms per gram) in dust from the infant’s bed versus living room dust.
RESULTS
There were only 173 (33.8%) of 512 infant bed dust samples
available for peanut protein analysis in the CoFAR observational
study. This was because of a large proportion of homes in which
no or less than 5 mg of dust was obtained from the infant’s bed.
Median peanut protein concentrations in the infant’s bed (10.7
mg/g; IQR, 2.5-42.38 mg/g) were also significantly lower than
peanut protein levels obtained from living room dust, where the
concentration was approximately 4 times higher (39.1mg/g; IQR,
13.4-150.60mg/g;P <.001). However, peanut protein levels in the
infant’s bed and living room floor were positively correlated (n5
138; rs 5 0.52; 95% CI, 0.39-0.63; P < .001; see Fig E2).
There was a trend toward a significant association between bed
dust EPE values and peanut SPT sensitization on univariate
analysis (n 5 172; OR, 1.08; 95% CI, 0.97-1.21; P 5 .16); how-
ever, this was lost on multivariate analysis (n 5 132; OR, 1.05;
95% CI, 0.92-1.20; P 5 .49) adjusting for ethnicity, egg SPT
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wheal diameter, and cow’s milk SPT wheal diameter. There was
no significant association between infant bed dust EPE and PA
on univariate LR analysis for EPE (n 5 109; OR, 0.93; 95% CI
%, 0.80-1.06; P 5 .27). There was no interaction between AD
or AD severity and bed dust EPE on peanut SPT sensitization
or likely allergy.
DISCUSSION
The lack of association between peanut protein levels in infant
bed dust and peanut sensitization/PA is not surprising because
peanut protein levels in bed dust correlate best with individual
peanut consumptionE1 and most infants recruited to CoFAR
would not have been eating peanut at this stage. This is reflected
in the lower median peanut protein concentration found in the
infant’s bed compared with that in living room dust. The living
room is the area that reflects the passage of most members of
the family and thus the contribution of household peanut con-
sumption to EPE. Furthermore, with the low number of dust sam-
ples and complete data sets we had using infant bed dust samples,
we were underpowered to show an effect.
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FIG E1. A, Multivariate stratified predictive probability for the effect of EPE (displayed in log2 [microgram
per gram] units and untransformed [microgram per gram] units) for peanut SPT sensitization in all children,
children with a history of AD, and children with a history of severe AD. Results are adjusted for egg
SPT wheal diameter, hay fever, maternal peanut consumption during pregnancy, and breast-feeding.
B, Multivariate stratified predictive probability for the effect of EPE (displayed in log2 [microgram per
gram] units and untransformed [microgram per gram] units) for peanut SPT sensitization in all children,
children with a history of AD, and children with a history of severe AD. Results are adjusted for egg and
milk wheal diameter and ethnicity.
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FIG E2. Scatter plot of peanut protein concentration in bed versus living
room dust. The Spearman tank correlation coefficient (rs) was 0.521
(P < .001).
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TABLE E1. CoFAR demographics from the included group (n 5 359) with available living room dust versus the excluded group
(n 5 153) and whole cohort (n 5 512)*
Included
group
Variable
included
group
Percentage
of variable
included
group
Excluded
group
Variable
excluded
group
Percentage
of variable
excluded
group
P
value
Whole
CoFAR
cohort
Variable
whole
cohort
Percentage
of variable
in cohort
Peanut SPT sensitization >_3 mm 359 196 54.6% 153 80 52.3% .38 512 276 53.9%
Peanut sIgE >_0.35 kU/mL 359 214 59.6% 153 91 59.5% .96 512 305 59.6%
Likely PA (sIgE >_5 kU/ml) 209 89 42.6% 99 45 45.5% .40 308 134 43.5%
History of infantile AD 359 332 92.5% 153 139 90.8% .28 512 471 92.0%
Maximum AD severity before study entry
No AD (0) 359 27 7.5% 153 14 9.2% .28 512 41 8.0%
Mild (3-4) 359 35 9.7% 153 17 11.1% .41 512 52 10.2%
Moderate (5-6) 359 102 28.4% 153 47 30.7% .34 512 149 29.1%
Severe (7-9) 359 195 54.3% 153 75 49.0% .04 512 270 52.7%
Nonwhite ethnicity 359 81 22.6% 153 51 33.3% <.01 512 380 74.2%
FLG null mutation (excluding nonwhite
subjects)
275 41 14.9% 101 15 14.9% .98 376 56 14.9%
Parental report of hay fever ever in the child 353 31 8.8% 148 11 7.4% .33 501 42 8.4%
Male sex 357 240 67.2% 153 103 67.3% .97 512 345 67.4%
Maternal history of atopy or asthma 356 243 68.3% 153 102 66.7% .52 509 345 67.8%
Paternal history of atopy or asthma 350 217 62.0% 150 89 59.3% .31 500 306 61.2%
Maternal history of AD 245 87 35.5% 97 28 28.9% .02 342 115 33.6%
Paternal history of AD 215 71 33.0% 85 27 31.8% .69 300 98 32.7%
Peanut consumption during pregnancy 352 295 83.8% 152 124 81.6% .28 504 419 83.1%
Peanut consumption during breast-feeding 299 179 59.9% 133 64 48.1% <.01 432 243 56.3%
Peanut present in house while breast-feeding 358 271 75.7% 153 107 69.9% .02 511 378 74.0%
Older siblings 359 148 41.2% 153 54 35.3% .02 512 202 39.5%
Egg SPT wheal diameter, median (IQR) 358 7.0 (4.0-10.5) 153 7.5 (4.3-11.0) .32 511 7.5 (4.0-10.5)
Cow’s milk SPT wheal diameter,
median (IQR)
356 5.0 (0.0-9.0) 155 4.0 (0.0-9.0) .69 511 5.0 (0.0-9.0)
Breast-feeding duration (mo), median (IQR) 359 5.0 (1.0-9.0) 153 5.0 (2.0-9.0) .15 512 5.0 (2.0-9.0)
Maternal age at baseline (y), median (IQR) 357 32.0 (28.0-35.0) 153 32.0 (28.5-35.0) .78 510 32.0 (28.0-35.0)
Child’s age at baseline assessment (mo),
median (IQR)
359 9.0 (7.0-12.0) 153 9.0 (7.0-12.0) .64 512 9 (7.0-12.0)
EPE (mg/g) in living room dust 359 39.1 (13.4-150.6) 153 Not available 359 39.1 (13.4-150.6)
EPE (mg/g) in infant bed dust 172 10.7 (2.5-42.8) 340 Not available 172 10.7 (2.5-42.8)
Statistically significant values (P < .05) are shown in boldface.
*Numbers and percentages of count data or medians (IQRs) of continuous factors and EPE values are shown.
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